2-47408415-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.226C>T(p.Gln76*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. Q76Q) has been classified as Benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
- Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MSH2 | NM_000251.3 | c.226C>T | p.Gln76* | stop_gained | Exon 2 of 16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MSH2 | ENST00000233146.7 | c.226C>T | p.Gln76* | stop_gained | Exon 2 of 16 | 1 | NM_000251.3 | ENSP00000233146.2 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:2
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
The substitution creates a nonsense variant, which changes a Glutamine to a premature stop codon, and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been reported in several individuals with Lynch syndrome (Stormorken 2005, Sjursen 2010, Bonnet 2012). MSH2 Gln76Ter was also observed in multiple members of a large Kuwaiti family meeting Amsterdam Criteria; three members of this family presented in childhood with lymphoma, and two of these children were confirmed to be homozygous for this variant (Scott 2007, Marafie 2009). This variant is considered pathogenic. -
not provided Pathogenic:2
- -
This variant is denoted MSH2 c.226C>T at the cDNA level and p.Gln76Ter (Q76X) at the protein level. The substitution creates a nonsense variant, which changes a Glutamine to a premature stop codon (CAG>TAG), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been reported in several individuals meeting Amsterdam II Criteria or Bethesda Guidelines for Lynch syndrome (Stormorken 2005, Sjursen 2010, Bonnet 2012). MSH2 Gln76Ter was also observed in multiple members of a large Kuwaiti family meeting Amsterdam Criteria; three members of this family presented in childhood with lymphoma and café-au-lait macules, and two of these children were confirmed to be homozygous for this variant (Scott 2007, Marafie 2009). Results from several functional assays in cells homozygous for MSH2 Gln76Ter were consistent with observations from MSH2 knockout mice, which have demonstrated reduced RAD51 loci and increased chromosome damage after ionizing radiation (Barwell 2007). This variant is considered pathogenic. -
Lynch-like syndrome Pathogenic:1
- -
Lynch syndrome Pathogenic:1
Coding sequence variation introducing premature termination codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln76*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome and/or mediastinal T-cell non-Hodgkin lymphoma (PMID: 16034045, 17601929, 19669601, 20587412, 22480969, 28874130). It has also been observed to segregate with disease in related individuals. Invitae’s Lynch syndrome clinical variant model, which takes into account the clinical and family history, age, sex, and reported ancestry of multiple individuals with this MSH2 variant, predicts that it is pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model developed at Invitae that incorporates the clinical features of 1,370,736 individuals referred for testing at Invitae. ClinVar contains an entry for this variant (Variation ID: 90945). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q76* pathogenic mutation (also known as c.226C>T), located in coding exon 2 of the MSH2 gene, results from a C to T substitution at nucleotide position 226. This changes the amino acid from a glutamine to a stop codon within coding exon 2. This alteration has been reported in a patient diagnosed with colorectal cancer at age 59 whose tumor showed absent staining for the MSH2 protein via immunohistochemistry (Stormorken A et al. J. Clin. Oncol. 2005 Jul;23(21):4705-12). It has also been reported in two large and highly consanguineous families in Kuwait who meet Amsterdam criteria (Marafie MJ et al. Fam. Cancer 2009;8(4):289-98). In one of these families, three siblings who were homozygous for this alteration developed non-Hodgkin lymphoma and pigmentary skin abnormalities in early childhood, consistent with a diagnosis of constitutional mismatch repair-deficiency (CMMR-D) syndrome; their parents, who were first cousins, were presymptomatic heterozygous carriers of this alteration (Scott RH et al. J. Med. Genet. 2007 Jul;44(7):e83). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at